CareDx (CDNA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Voting matters and shareholder proposals
Election of five directors: Fred E. Cohen, R. Bryan Riggsbee, Suresh Gunasekaran, Michael D. Goldberg, and John W. Hanna, with board recommendation to vote for all nominees.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory approval of named executive officer compensation, with board recommendation to vote for.
Advisory vote on the frequency of future say-on-pay votes, with board recommendation for annual votes.
Approval of an amendment to the 2024 Equity Incentive Plan, with board recommendation to vote for.
Board of directors and corporate governance
Board recommends all director nominees for election at the 2026 annual meeting.
Proxies are authorized to vote on other business that may arise at the meeting or any adjournment.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included, with board recommendation to approve.
Advisory vote on the frequency of future say-on-pay votes, with board recommendation for annual votes.
Amendment to the 2024 Equity Incentive Plan is up for approval.
Latest events from CareDx
- All agenda items, including director elections and equity plan amendment, were approved.CDNA
AGM 202611 Jun 2026 - Precision diagnostics focus, Naveris acquisition, and pipeline expansion drive growth and profitability.CDNA
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Stockholders to vote on 2025 executive compensation, with clarified bonus calculation methods.CDNA
Proxy filing5 Jun 2026 - Q1 revenue up 39%, pipeline expands with Naveris and AlloHeme, driving future growth.CDNA
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q1 2026 revenue up 39% to $118M, net income positive, guidance raised, and major M&A moves.CDNA
Q1 202629 Apr 2026 - Key votes include director elections, auditor ratification, and expanding the equity incentive plan.CDNA
Proxy filing28 Apr 2026 - AlloHeme enables highly sensitive, non-invasive relapse detection in AML/MDS post-HCT, launching in 2027.CDNA
Status update13 Apr 2026 - Strong growth, innovation, and market expansion drive leadership in transplant diagnostics.CDNA
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - 2025 revenue up 14% to $380M; 2026 guidance $420–$444M with strong growth and innovation.CDNA
Q4 202525 Feb 2026